Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P105: Decisional role of inter...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles

Bibliographic Details
Main Authors: Chiara Rusconi, Francesca Ricci, Vittorio R. Zilioli, Vincenzo Marasco, Eleonora Calabretta, Anna Guidetti, Cristina Muzi, Federico Mazzon, Margherita Smania, Martina Sollini, Erika Meli, Marcello Rodari, Emanuele Ravano, Roberto Cairoli, Paolo Corradini, Armando Santoro
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000890988.85828.9b
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000890988.85828.9b

Similar Items

  • P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
    by: Chiara Rusconi, et al.
    Published: (2023-08-01)
  • Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
    by: Armando Santoro, et al.
    Published: (2020-01-01)
  • P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
    by: Ya.K. Mangasarova, et al.
    Published: (2022-10-01)
  • P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
    by: Chiara Rusconi, et al.
    Published: (2022-10-01)
  • P124 (0115) RETROSPECTIVE REAL-LIFE STUDY OF THE BEGEV (BENDAMUSTINE, GEMCITABINE, VINORELBINE) REGIMEN IN HEAVILY PRETREATED, RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
    Published: (2018-10-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs